131 related articles for article (PubMed ID: 20190395)
1. Effect of multimerization of a linear Arg-Gly-Asp peptide on integrin binding affinity and specificity.
Jin ZH; Furukawa T; Waki A; Akaji K; Coll JL; Saga T; Fujibayashi Y
Biol Pharm Bull; 2010; 33(3):370-8. PubMed ID: 20190395
[TBL] [Abstract][Full Text] [Related]
2. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
Haubner R; Wester HJ; Reuning U; Senekowitsch-Schmidtke R; Diefenbach B; Kessler H; Stöcklin G; Schwaiger M
J Nucl Med; 1999 Jun; 40(6):1061-71. PubMed ID: 10452325
[TBL] [Abstract][Full Text] [Related]
3. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
[TBL] [Abstract][Full Text] [Related]
4. Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5).
Zannetti A; Del Vecchio S; Iommelli F; Del Gatto A; De Luca S; Zaccaro L; Papaccioli A; Sommella J; Panico M; Speranza A; Grieco P; Novellino E; Saviano M; Pedone C; Salvatore M
Clin Cancer Res; 2009 Aug; 15(16):5224-33. PubMed ID: 19671851
[TBL] [Abstract][Full Text] [Related]
5. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
6. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive visualization and quantification of tumor αVβ3 integrin expression using a novel positron emission tomography probe, 64Cu-cyclam-RAFT-c(-RGDfK-)4.
Jin ZH; Furukawa T; Galibert M; Boturyn D; Coll JL; Fukumura T; Saga T; Dumy P; Fujibayashi Y
Nucl Med Biol; 2011 May; 38(4):529-40. PubMed ID: 21531290
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging.
Su ZF; Liu G; Gupta S; Zhu Z; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2002; 13(3):561-70. PubMed ID: 12009947
[TBL] [Abstract][Full Text] [Related]
9. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
[TBL] [Abstract][Full Text] [Related]
10. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
11. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
12. A new cyclic RGD peptide dimer for integrin αvβ3 imaging.
Ma H; Hao P; Zhang L; Ma C; Yan P; Wang RF; Zhang CL
Eur Rev Med Pharmacol Sci; 2016; 20(4):613-9. PubMed ID: 26957261
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of ligand recognition by integrin alpha5beta 1. II. Specificity of arg-gly-Asp binding is determined by Trp157 OF THE alpha subunit.
Humphries JD; Askari JA; Zhang XP; Takada Y; Humphries MJ; Mould AP
J Biol Chem; 2000 Jul; 275(27):20337-45. PubMed ID: 10764747
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes.
Dijkgraaf I; Rijnders AY; Soede A; Dechesne AC; van Esse GW; Brouwer AJ; Corstens FH; Boerman OC; Rijkers DT; Liskamp RM
Org Biomol Chem; 2007 Mar; 5(6):935-44. PubMed ID: 17340009
[TBL] [Abstract][Full Text] [Related]
15. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
16. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
17. Fast clearing RGD-based near-infrared fluorescent probes for in vivo tumor diagnosis.
Cao J; Wan S; Tian J; Li S; Deng D; Qian Z; Gu Y
Contrast Media Mol Imaging; 2012; 7(4):390-402. PubMed ID: 22649045
[TBL] [Abstract][Full Text] [Related]
18. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin.
Choi Y; Kim E; Lee Y; Han MH; Kang IC
Proteomics; 2010 Jan; 10(1):72-80. PubMed ID: 19882657
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using compartment model.
Guo N; Lang L; Gao H; Niu G; Kiesewetter DO; Xie Q; Chen X
Mol Imaging Biol; 2012 Dec; 14(6):743-52. PubMed ID: 22437879
[TBL] [Abstract][Full Text] [Related]
20. In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors.
Jin ZH; Josserand V; Foillard S; Boturyn D; Dumy P; Favrot MC; Coll JL
Mol Cancer; 2007 Jun; 6():41. PubMed ID: 17565663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
